Nuclear medicine device trial for treating liver cancer launched in US

The University of Missouri (Mizzou) has initiated its first clinical trial in the US using a novel nuclear medicine device called Eye90 microspheres to treat unresectable liver tumors, including hepatocellular carcinoma and metastatic colorectal cancer. The treatment began on February 9 at the Ellis Fischel Cancer Center. Eye90 microspheres are specialized glass beads embedded with the radioisotope yttrium-90 (Y-90) and are uniquely radiopaque, allowing physicians to visualize and precisely target liver tumors during treatment via CT scans. This advancement addresses a significant limitation of previous Y-90 bead therapies, which were invisible on standard imaging, forcing doctors to rely on less precise methods. Mizzou’s Research Reactor (MURR) is the exclusive US manufacturer of these microspheres, continuing a legacy of glass microsphere technology dating back to the 1980s. The development of Eye90 involved extensive preclinical safety and effectiveness studies, including successful trials in dogs with naturally occurring liver tumors